ALK-Abello A/S

Alk-Abello is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergies. Co.'s product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. Co.'s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Co.'s emergency treatments product offering comprises products for the management of anaphylaxis. Co.'s allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests.
  • TickerALK B
  • ISINDK0060027142
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

ALK-ABELLO A/S sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of ALK-ABELLO A/S (DK), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date July 3, 2020, the closing price was DKK 1,785.00 and its potential was estimated at DKK 2,205.60.

André Thormann ...
  • Benjamin Silverstone
  • Fredrik Ivarsson
  • Jan Erik Gjerland
  • Jannick Lindegaard Denholt
  • Jonas Bru Lien
  • Karl Fredrik Schjøtt-Pedersen
  • Tobias Kaj
  • Victor Forssell

Talking Points - NNIT (Hold): Currently resilient to COVID-19

Pandora (Hold) Post-results comment: We are tempted, but not just yet Q1 below consensus, margins hit by Novo Nordisk Cost programme positive, but risk remains; up to HOLD

Jesper Ingildsen

ALK-Abello (Hold, TP: DKK2020.00) - More resilient than expected

ALK-Abello (ALKB DC, Hold) - More resilient than expected (15 pages)

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

ALK-Abello - Allergic to bad results

Q1’20 EBITDA 78% over company-collected consensus FY’20 guidance (as presented in February) maintained Target price up to DKK 1,960 (1,830); BUY rating intact

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

ALK-Abello - Q1’20 strong results and guidance maintained

Strong EBITDA in Q1’20 Guidance for FY’20 maintained We expect a positive share reaction today

Jesper Ingildsen

ALK-Abello (Hold, TP: DKK1925.00) - Covid-19 hit too early to assess

ALK-Abello (ALKB DC, Hold) - Covid-19 hit too early to assess (17 pages)

Håkon Astrup ...
  • Jesper Ingildsen
  • Karl-Johan Bonnevier
  • Mattias Holmberg
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Frank Maaø ...
  • Håkon Astrup
  • Jesper Ingildsen
  • Martin Arnell
  • Nicolas McBeath
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Christer Magnergård ...
  • Christoffer Wang Bjørnsen
  • Jesper Ingildsen
  • Jon Masdal
  • Martin Arnell
  • Martin Hoang Nguyen
  • Mattias Holmberg
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Rune Majlund Dahl
  • Tomi Railo

Northern Lights

Christoffer Wang Bjørnsen ...
  • Jesper Ingildsen
  • Martin Arnell
  • Mats Bye
  • Nicolas McBeath
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Håkon Astrup ...
  • Jesper Ingildsen
  • Joachim Gunell
  • Mats Bye
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

ALK-ABELLO A/S sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of ALK-ABELLO A/S (DK), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date July 3, 2020, the closing price was DKK 1,785.00 and its potential was estimated at DKK 2,205.60.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch